Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.58 |
| ▸ | TNKS | O95271 | 1/20 | 0.55 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | STAT1 | P42224 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | GABRP | O00591 | 5/20 | 0.47 |
| ▸ | GABRD | O14764 | 5/20 | 0.47 |
| ▸ | GABRA1 | P14867 | 5/20 | 0.47 |
| ▸ | GABRB1 | P18505 | 5/20 | 0.47 |
| ▸ | GABRG2 | P18507 | 5/20 | 0.47 |
| ▸ | GABRB3 | P28472 | 5/20 | 0.47 |
| ▸ | GABRA5 | P31644 | 5/20 | 0.47 |
| ▸ | GABRA3 | P34903 | 5/20 | 0.47 |
| ▸ | GABRA2 | P47869 | 5/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14307644 | 0.85 | ERAP1 (0.61) | ERAP1CYP1A1CYP1A2CYP1B1KDM4E | |
| SCHEMBL5425943 | 0.82 | ERAP1 (0.79) | ERAP1CYP1A1CYP1A2CYP1B1KDM4E | |
| SCHEMBL3091877 | 0.82 | ERAP1 (0.58) | ERAP1CYP1A1CYP1A2CYP1B1KDM4E | |
| SCHEMBL4449250 | 0.81 | ERAP1 (0.68) | ERAP1TNKSCYP1A1CYP1A2CYP1B1 | |
| SCHEMBL8608 | 0.81 | KDM4E (0.59) | TNKSCYP1A2KDM4EALDH1A1NPC1 | |
| SCHEMBL7120381 | 0.80 | ABCB1 (0.59) | ERAP1CYP1A1CYP1A2CYP1B1KDM4E | |
| SCHEMBL28532725 | 0.80 | ERAP1 (0.56) | ERAP1CYP1A1CYP1A2CYP1B1KDM4E | |
| SCHEMBL29839920 | 0.78 | TNKS (0.53) | TNKSKDM4EALDH1A1NPC1RAB9A | |
| SCHEMBL8118207 | 0.78 | ERAP1 (0.72) | ERAP1CYP1A1CYP1A2CYP1B1KDM4E | |
| SCHEMBL3079215 | 0.78 | ERAP1 (0.63) | ERAP1CYP1A1CYP1A2CYP1B1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140155321-A1 | Polypeptides and Their Use | NOVABIOTICS LIMITED (GB) | 2014-06-05 | — | — | US | disclosed |
| US-20100267653-A1 | USE OF COUMARIN DERIVATIVES IN ANTIFUNGAL THERAPY | NOVABIOTICS LIMITED (GB) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267653-A1 | USE OF COUMARIN DERIVATIVES IN ANTIFUNGAL THERAPY | DPM1, XPO5, NISCH | ERAP1 1665/4885TNKS 4011/4885CYP1A1 315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.